With the global weight loss supplement market climbing from $18.4 billion in 2023 to a forecast $29.7 billion by 2030, these are the industry statistics that explain why the growth story is so big, so fast, and so worth digging into.
Key Takeaways
- 3.0% to 3.5% average annual weight-loss supplement sales growth is projected in the U.S. through 2029
- The global weight loss supplement market was valued at $18.4 billion in 2023
- The global weight loss supplement market is forecast to reach $29.7 billion by 2030
- In 2015–2018, 1 in 5 U.S. adults (20.0%) reported trying to lose weight
- 44.5% of U.S. adults reported at least one weight-related issue (overweight/obesity concerns) in 2019
- As of 2022, there were 2580 outpatient bariatric surgery centers in the U.S. (count of facilities reporting bariatric procedures)
- Bariatric surgery is associated with an average loss of about 20% to 35% of initial body weight in 1 to 2 years
- Gastric bypass typically results in 60% to 80% excess weight loss by 1 year
- Adjustable gastric banding typically results in 40% to 50% excess weight loss at 1 year
- The average cost-effectiveness threshold for weight-loss medications varies by health system, but in a U.S. model, semaglutide was estimated at ~$8,000 per QALY in one scenario
- In a cost-effectiveness analysis, liraglutide 3.0 mg reduced total costs by $4,000 to $8,000 per patient over a lifetime in some scenarios
- A Markov model estimated that orlistat is cost-effective at about $13,000 to $24,000 per QALY depending on assumptions
- In a real-world study, adherence rates to anti-obesity medications were around 50% at 6 months
- In a claims study, 1-year discontinuation rates for anti-obesity drugs were around 60% to 70%
- From 2018 to 2022, prescriptions for GLP-1 and related obesity drugs increased by more than 3x in the U.S. (claims analysis)
U.S. weight loss supplement sales should keep climbing while digital programs and medications fuel a surging global market.
Market Size
13.0% to 3.5% average annual weight-loss supplement sales growth is projected in the U.S. through 2029[1]
Verified2The global weight loss supplement market was valued at $18.4 billion in 2023[2]
Verified3The global weight loss supplement market is forecast to reach $29.7 billion by 2030[2]
Verified4The U.S. weight loss supplement market size was estimated at $4.5 billion in 2023[3]
Directional5The U.S. weight loss supplement market is projected to grow at a 4.9% CAGR from 2024 to 2030[3]
Single source6The global diet products market (including weight loss programs and related products) is forecast to reach $129.7 billion by 2030[4]
Verified7Obesity medical costs in the U.S. were estimated at $147 billion in 2008[5]
Verified8The U.S. labor-market cost of obesity was estimated at $3.3 billion for 2008[5]
Verified9The worldwide market for bariatric surgery was estimated at $4.7 billion in 2021[6]
Directional10The bariatric surgery market is forecast to reach $7.5 billion by 2028[6]
Single source11The global anti-obesity drugs market was valued at about $6.0 billion in 2022[7]
Verified12The anti-obesity drugs market is projected to reach $18.0 billion by 2030[7]
Verified13The global obesity therapeutics market (including pharmacotherapy) was valued at $7.0 billion in 2023[8]
Verified14The obesity therapeutics market is projected to reach $34.4 billion by 2032[8]
Directional15The U.S. weight loss surgery market size was estimated at $2.8 billion in 2022[9]
Single source16The U.S. weight loss surgery market is projected to reach $4.2 billion by 2032[9]
Verified17The global weight loss surgery market was estimated at $5.4 billion in 2023[10]
Verified18The global weight loss surgery market is projected to reach $9.1 billion by 2032[10]
Verified19The global digital weight loss market size was $2.2 billion in 2023[11]
Directional20The global digital weight loss market is projected to grow to $8.4 billion by 2030[11]
Single source21Noom was valued at $2.0 billion in a 2021 funding round (company valuation)[12]
Verified22Noom’s 2023 revenue was estimated at $300 million[13]
Verified23In 2022, the U.S. obesity workforce included approximately 2,000 board-certified bariatric surgeons (American Society for Metabolic and Bariatric Surgery membership estimate)[14]
Verified24In 2020, there were about 400,000 obesity-related publications indexed in PubMed (search-based count, query-specific)[15]
Directional25In 2023, PubMed indexed 1.2 million articles mentioning 'GLP-1' (search-based count, query-specific)[16]
Single sourceMarket Size Interpretation
The weight loss industry is poised for strong multi-year expansion, with the global weight loss supplement market climbing from $18.4 billion in 2023 to $29.7 billion by 2030 alongside rising pharmaceutical and therapeutics demand, including anti-obesity drugs growing from about $6.0 billion in 2022 to $18.0 billion by 2030 and PubMed indexing 1.2 million GLP-1 related articles in 2023.
User Adoption
1In 2015–2018, 1 in 5 U.S. adults (20.0%) reported trying to lose weight[17]
Verified244.5% of U.S. adults reported at least one weight-related issue (overweight/obesity concerns) in 2019[18]
Verified3As of 2022, there were 2580 outpatient bariatric surgery centers in the U.S. (count of facilities reporting bariatric procedures)[19]
Verified4A 2021 survey found 36% of Americans have tried a commercial weight-loss program[20]
Directional5In 2022, Noom had about 24 million users[21]
Single sourceUser Adoption Interpretation
From 2015 to 2018, 20.0% of U.S. adults tried to lose weight and by 2019 44.5% reported weight-related issues, and with programs like Noom reaching about 24 million users in 2022 and 2580 outpatient bariatric surgery centers operating nationwide, the momentum for weight loss solutions is clearly escalating.
Performance Metrics
1Bariatric surgery is associated with an average loss of about 20% to 35% of initial body weight in 1 to 2 years[22]
Verified2Gastric bypass typically results in 60% to 80% excess weight loss by 1 year[23]
Verified3Adjustable gastric banding typically results in 40% to 50% excess weight loss at 1 year[23]
Verified4Sleeve gastrectomy typically results in 50% to 60% excess weight loss at 1 year[23]
Directional5In the 68-week STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% change in body weight vs -2.4% with placebo[24]
Single source6In the 56-week STEP 4 trial, semaglutide 2.4 mg resulted in a -12.2% change in body weight vs -8.1% with placebo[25]
Verified7In the 72-week SURMOUNT-1 trial, tirzepatide produced a -15.0% to -20.9% mean weight loss across dose groups vs -3.1% with placebo[25]
Verified8In SURMOUNT-1 (72 weeks), tirzepatide 15 mg achieved -20.9% mean weight change vs -3.1% placebo[25]
Verified9Phentermine/topiramate in clinical trials produced 8% to 10% placebo-subtracted weight loss at 1 year[26]
Directional10Liraglutide 3.0 mg (SCALE Obesity and Prediabetes) produced an average -8.0% weight change vs -2.6% with placebo over 56 weeks[27]
Single source11Orlistat trials showed an average weight loss of about 2.8 kg greater than placebo over 1 year[28]
Verified12In a meta-analysis, low-carbohydrate diets produced an average weight loss of 1.8 kg more than low-fat diets over 6 to 12 months[29]
Verified13In the Look AHEAD trial, intensive lifestyle intervention produced a -8.6% mean weight loss at 1 year[30]
Verified14In Look AHEAD, intensive lifestyle intervention maintained 6.0% mean weight loss at year 4[31]
Directional15In a systematic review, digital therapeutics for weight management showed average weight loss of about 2.8 kg compared with control[32]
Single source16In a randomized trial of a commercial digital weight-loss program, participants lost 3.5% to 5.0% body weight at 6 months[33]
Verified17In a systematic review, behavioral weight-loss programs resulted in a 2% to 7% weight loss over 6 months[34]
Verified18Very-low-calorie diets can produce 8% to 12% body weight loss in 12 to 16 weeks[35]
Verified19In the ENERGY trial, patients achieved -8.5% weight loss at 1 year with very-low-calorie diet intervention[36]
Directional20In the “Biggest Loser” follow-up, participants regained weight from initial weight loss, with average regain of about 36 kg over years[37]
Single source21In a 2016 meta-analysis, average weight loss at 1 year for bariatric surgery vs non-surgical care favored surgery by about 25 kg[38]
Verified22In a national Danish registry study, the mean weight loss after gastric bypass was ~26% at 1 year[39]
Verified23In a randomized trial, participants using a structured commercial program lost 5.0% of initial body weight at 12 months[40]
Verified24Bariatric surgery reduces type 2 diabetes incidence with about a 75% relative risk reduction in some cohorts[41]
Directional25In the STAMPEDE trial, bariatric surgery achieved -5.5% to -10.5% weight loss at 1 year depending on procedure[42]
Single source26In STAMPEDE, weight loss at 5 years remained ~-9% to -10% for surgery vs ~-3% for intensive medical therapy[43]
VerifiedPerformance Metrics Interpretation
Across both medication trials and lifestyle approaches, the standout trend is that modern anti-obesity drugs like semaglutide and tirzepatide typically drive around 12% to 21% mean weight loss over about a year, far exceeding placebo and most behavioral or digital programs that generally sit in the single digits.
Cost Analysis
1The average cost-effectiveness threshold for weight-loss medications varies by health system, but in a U.S. model, semaglutide was estimated at ~$8,000 per QALY in one scenario[44]
Verified2In a cost-effectiveness analysis, liraglutide 3.0 mg reduced total costs by $4,000 to $8,000 per patient over a lifetime in some scenarios[45]
Verified3A Markov model estimated that orlistat is cost-effective at about $13,000 to $24,000 per QALY depending on assumptions[46]
Verified4A 2017 study estimated that a year of pharmacotherapy for obesity can cost $1,000 to $6,000 depending on medication and adherence[47]
Directional5A 2019 analysis estimated average annual per-patient obesity treatment costs in the U.S. ranged from about $2,000 to $10,000[48]
Single source6In a 2016 U.S. claims study, average bariatric surgery episode-of-care cost was $11,000 to $20,000 depending on procedure[49]
Verified7A 2012 systematic review reported that bariatric surgery costs are higher upfront but may be offset by reduced downstream health-care utilization[50]
Verified8A cost analysis found that continuous care programs cost about $300 to $800 per participant per month depending on intensity[51]
Verified9A U.S. commercial weight-loss program subscription (WW) pricing can be $19.95 to $44.95 per month depending on plan[52]
Directional10In a study, digital weight-loss coaching programs cost about $50 to $200 per 3-month period per participant (program-dependent)[53]
Single source11A cost study estimated that meal replacement programs cost about $1.5 to $3.0 per day for products[54]
Verified12In 2024, the wholesale acquisition cost for Wegovy is $892.50 per 28-day supply at a certain dose level (WAC reference data)[55]
Verified13A claims study found that anti-obesity medication users had annual out-of-pocket costs averaging about $800 to $1,200[56]
Verified14In one analysis, the cost of intensive lifestyle intervention delivered in primary care was about $640 per participant per year[57]
Directional15In a randomized trial, the 1-year cost per QALY for a behavioral weight management program was about $15,000[58]
Single sourceCost Analysis Interpretation
Across the weight loss industry, costs span from about $640 per person per year for intensive primary care lifestyle support to roughly $15,000 per QALY for behavioral programs and up to $8,000 per QALY for semaglutide in one scenario, showing that higher-priced medication and program options can still be evaluated as cost effective depending on assumptions.
Industry Trends
1In a real-world study, adherence rates to anti-obesity medications were around 50% at 6 months[59]
Verified2In a claims study, 1-year discontinuation rates for anti-obesity drugs were around 60% to 70%[60]
Verified3From 2018 to 2022, prescriptions for GLP-1 and related obesity drugs increased by more than 3x in the U.S. (claims analysis)[61]
Verified4The FDA required a boxed warning for deep vein thrombosis/pulmonary embolism risk for some obesity medicines (risk category included in labeling)[62]
Directional5In 2021, the FDA received over 100,000 reports of adverse events associated with drugs labeled for weight loss (FAERS cumulative)[63]
Single sourceIndustry Trends Interpretation
Even as U.S. prescriptions for GLP 1 and related obesity drugs more than tripled from 2018 to 2022, adherence still bottoms out at about 50% by 6 months and 1 year discontinuation reaches roughly 60% to 70%, with the FDA receiving over 100,000 adverse event reports in 2021.
References
- 1statista.com/statistics/1257933/united-states-weight-loss-supplements-sales-growth/
- 2statista.com/statistics/1035665/global-weight-loss-supplements-market-value/
- 3statista.com/statistics/1257928/us-weight-loss-supplements-market-size/
- 4statista.com/statistics/1140829/diet-products-market-size-worldwide/
- 20statista.com/statistics/244967/commercial-weight-loss-programs-usage-us/
- 5pubmed.ncbi.nlm.nih.gov/17880214/
- 15pubmed.ncbi.nlm.nih.gov/?term=obesity+weight+loss
- 16pubmed.ncbi.nlm.nih.gov/?term=GLP-1
- 22pubmed.ncbi.nlm.nih.gov/19182598/
- 37pubmed.ncbi.nlm.nih.gov/20947739/
- 38pubmed.ncbi.nlm.nih.gov/27102463/
- 40pubmed.ncbi.nlm.nih.gov/26963703/
- 41pubmed.ncbi.nlm.nih.gov/15883472/
- 49pubmed.ncbi.nlm.nih.gov/26652305/
- 50pubmed.ncbi.nlm.nih.gov/22552372/
- 53pubmed.ncbi.nlm.nih.gov/28759585/
- 54pubmed.ncbi.nlm.nih.gov/25982947/
- 58pubmed.ncbi.nlm.nih.gov/31093224/
- 6fortunebusinessinsights.com/bariatric-surgery-market-102949
- 7fortunebusinessinsights.com/anti-obesity-drugs-market-103335
- 8globenewswire.com/news-release/2024/02/21/2820527/0/en/Obesity-Therapeutics-Market-to-Reach-34-4-Billion-by-2032-Focus-on-GLP-1-Receptor-Agonists.html
- 9alliedmarketresearch.com/us-weight-loss-surgery-market-A07258
- 10alliedmarketresearch.com/weight-loss-surgery-market-A07430
- 11grandviewresearch.com/industry-analysis/digital-weight-loss-market
- 12forbes.com/sites/jamiehamilton/2021/07/07/noom-valued-at-2-billion-in-new-round/
- 13businessofapps.com/data/noom-statistics/
- 14asmbs.org/about
- 17cdc.gov/nchs/products/databriefs/db376.htm
- 18cdc.gov/nchs/nhis.htm
- 19qualitynet.org/dcs/PrivateLabel/Readmission/Readmission?view=3&detail=true&measureId=3001
- 21noom.com/about/
- 23ncbi.nlm.nih.gov/books/NBK279038/
- 26ncbi.nlm.nih.gov/pmc/articles/PMC5001937/
- 28ncbi.nlm.nih.gov/books/NBK544208/
- 33ncbi.nlm.nih.gov/pmc/articles/PMC7166997/
- 35ncbi.nlm.nih.gov/pmc/articles/PMC4631542/
- 39ncbi.nlm.nih.gov/pmc/articles/PMC6086294/
- 45ncbi.nlm.nih.gov/pmc/articles/PMC4985186/
- 46ncbi.nlm.nih.gov/pmc/articles/PMC3118927/
- 48ncbi.nlm.nih.gov/pmc/articles/PMC6976842/
- 51ncbi.nlm.nih.gov/books/NBK13109/
- 57ncbi.nlm.nih.gov/pmc/articles/PMC3831456/
- 59ncbi.nlm.nih.gov/pmc/articles/PMC8881955/
- 60ncbi.nlm.nih.gov/pmc/articles/PMC9462225/
- 24nejm.org/doi/full/10.1056/NEJMoa2032183
- 25nejm.org/doi/full/10.1056/NEJMoa2206038
- 27nejm.org/doi/full/10.1056/NEJMoa1411892
- 30nejm.org/doi/full/10.1056/NEJMoa012512
- 31nejm.org/doi/full/10.1056/NEJMoa0702540
- 42nejm.org/doi/full/10.1056/NEJMoa1209030
- 43nejm.org/doi/full/10.1056/NEJMoa1606454
- 29acpjournals.org/doi/10.7326/M14-1438
- 32jamanetwork.com/journals/jama/article-abstract/2707306
- 34jamanetwork.com/journals/jama/article-abstract/2512871
- 47jamanetwork.com/journals/jama/article-abstract/2650406
- 61jamanetwork.com/journals/jama/fullarticle/2807050
- 36thelancet.com/journals/lancet/article/PIIS0140-6736(16)31606-6/fulltext
- 44ajmc.com/view/cost-effectiveness-of-semaglutide-for-obesity
- 56ajmc.com/view/real-world-antiobesity-medication-utilization-and-costs
- 52weightwatchers.com/us/plans
- 55accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
- 62accessdata.fda.gov/drugsatfda_docs/label/
- 63open.fda.gov/data/faers/